Efficacy of trabectedin in metastatic solitary fibrous tumor

Loïc Chaigneau, Elsa Kalbacher, Antoine Thiery-Vuillemin, Christine Fagnoni-Legat, Nicolas Isambert, Lionel Aherfi, Julien Pauchot, Delphine Delroeux, Stephanie Servagi-Vernat, Laura Mansi, Xavier Pivot, Loïc Chaigneau, Elsa Kalbacher, Antoine Thiery-Vuillemin, Christine Fagnoni-Legat, Nicolas Isambert, Lionel Aherfi, Julien Pauchot, Delphine Delroeux, Stephanie Servagi-Vernat, Laura Mansi, Xavier Pivot

Abstract

Solitary fibrous tumor is a rare tumor type and has an unpredictable course. Local recurrence rate varies between 9 and 19%, and rate of metastatic involvement between 0 and 36 %. It is characterized by a typical architecture and immuno-histochemistry tests. The most important prognostic factor is the complete resection of primary tumor. Treatment of recurrences is not clearly established. If a solitary fibrous tumor is too advanced to allow surgical resection, radiotherapy and chemotherapy may be used. The most often used drugs are doxorubicine and\or ifosfamide. We report the case of man with metastatic solitary fibrous tumor treated with trabectedin, administered at a dose of 1.5 mg/m² every 3 weeks. After 3 cycles, metastases had significantly decreased. Recurrence of the disease was demonstrated 8 months after the start of trabectedin. This case shows that trabectedin is a possible treatment option.

Keywords: metastatic solitary fibrous tumor; trabectedin..

Conflict of interest statement

Conflict of interest: the authors report no conflicts of interest.

Figures

Figure 1
Figure 1
Lung biopsy; several metastatic micronodules of SFT (HES × 10).
Figure 2
Figure 2
Biopsy; SFT is characterized by spindle cells with vescisular nuclei (HES × 40). All the tumoral cells are immunoreactive with CD34 (×40).
Figure 3
Figure 3
Computed tomografy scan on January 2009, before trabectedin.
Figure 4
Figure 4
Computed tomografy scan on March 2009, after 3 cycles of trabectedin.
Figure 5
Figure 5
Computed tomografy scan on June 2009, 2 months later the end of chemoterapy.

References

    1. FNCLCC and the French sarcoma group. Consolidation with high dose chemotherapy for responding patients to standard chemotherapy in advanced, metastatic. Not published results
    1. .
    1. England DM, Hochholzer L, Mc Carthy MJ. Localized benign and malignant fibrous tumors of the pleura. A clinicopathologic review of 223 cases. Am J Surg Pathol. 1989;13:640–58.
    1. Guillou L, Gebhard S, Coindre JM. Orbital and extraorbital giant cell angiofibroma: a giant cell-rich variant of solitary fibrous tumor? Clinicopathologic and immunhistochemical analysis of a series of a unifying concept. Am J Surg Pathol. 2000;24:971–9.
    1. Goodlad JR, Fletcher CDM. Solitary fibrous tumour arising at unusual sites: analysis of a series. Histopathology. 1991;19:515–22.
    1. Suster S, Nascimento AG, Miettinen M, et al. Solitary fibrous tumors of soft tissue. A clinicopathologic and immunohistochemical study of 12 cases. Am J Surg Pathol. 1995;19:1257–66.
    1. Brunnemann R, Ro JY, Ordonez NG, et al. Extrathoracic solitary fibrous tumor: a clinicopathologic study of 24 cases. Mod Pathol. 1999;12:1034–42.
    1. Hasegawa T, Matsuno Y, Shimoda T, et al. Extrathoracic solitary fibrous tumors: their histological variability and potentially aggressive behaviour. Hum Pathol. 1999;30:1464–73.
    1. Hanau CA, Miettinen M. Solitary fibrous tumor: histological and immunohisto-chemical spectrum of benign and malignant variants presenting at different sites. Hum Pathol. 1995;26:440–9.
    1. Guillou L, Gebhard S, Coindre JM. Lipomatous hemangiopericytoma: a fat-containing variant of solitary fibrous tumor? Clinicopathologic, immunohisto-chemical, and ultrastructural analysis of a series in favor of a unifying concept. Hum Pathol. 2000;31:1108–15.
    1. Scotto KW. ET-743: more than an innovative mechanism of action. Anticancer drugs. 2002;13:S3–6.
    1. Fayette J, Ray-Coquard I, Alberti L, et al. ET-743: a novel agent with activity in soft tissue sarcomas. The Oncologist. 2005;10:827–32.
    1. Demitri G D, Chawla SP, Von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcome after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009;27:4188–96.
    1. Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010;28:3107–14.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren